Jul 18, 2002|
Ranbaxy: Export bonanza
Numbers actually speak for themselves. Driven by sky rocketing performance in the overseas business, Ranbaxy Laboratories has declared 189% increase in net profits, with a strong topline growth of 46% (on a standalone basis). Operating margins leapfrogged more than 550 basis points, primarily on the back of high margin exports. The company has declared 3:5 bonus (i.e. 3 bonus shares for every 5 shares held).
|Operating Profit (EBDIT)
|Operating Profit Margin (%)
|Profit before Tax
|Profit after Tax/(Loss)
|Net profit margin (%)
|No. of Shares (eoy) (m)
|Diluted Earnings per share*
|P/E (at current price)
The highlight of the quarterly results was the strong performance recorded by Ranbaxy in the US markets. The US subsidiary of the company recorded 206% topline growth for the quarter. US markets now contribute 35% of the global (consolidated) sales of the company surpassing the contribution from the domestic markets (30%). While formulation exports grew by more than 140%, bulk exports were up 24%. The growth in formulation exports was driven primarily by anti-infective, Cefuroxime Axetil (Ceftin), which contributed approximately US$ 37 m (Rs 1.8 bn) to export sales.
It may be recalled that due to lack of any other player in the market with necessary approvals, Ranbaxy enjoys ‘technical’ monopoly (in generic version) for marketing anti-infective, Cefuroxime Axetil (Ceftin) in the US markets. The company has already enjoyed almost 5 months of exclusivity on the US$ 400 m drug and the exclusivity is likely to continue atleast for another 6 months. Ranbaxy has already mopped up US$ 37 m sales from this drug (till June'02) and currently enjoys more than 55% market share of the product. We expect sales from Cefuroxime Axetil (Ceftin) to touch US$ 90 m in the current year. Read more on Ceftin opportunity . All in all there was a sharp improvement in margins on account of high margin formulation exports, which has registered a 65% growth in the first half.
Ranbaxy - Exports led performance
The performance in the domestic market was however lackluster, primarily on account of 45% negative growth recorded by the company in the bulk drug business. This was due to planned reduction on account of increasing requirements to meet its internal formulation sales and also on account of giving preference to bulk exports vis'-a-vis' domestic market. Formulations sales in the domestic market are more or less in line with the industry growth rates.
The research spend of the company is steadily inching ahead, representing more than 5% of the company's sales. Ranbaxy recently announced an agreement to out-license its lead R&D molecule (RBX-2258) for the treatment of Benign Prostrate Hyperplasia (BPH) to Schwarz Pharma of Germany. The company would receive milestone payments (excluding royalties) of up to US$ 42 m from Schwarz. Ranbaxy has received upfront payment of Rs 302 m (US$ 6.1 m) from the deal. The company has not disclosed details on royalty payment terms (percentage). Schwarz Pharma would get the rights to develop, market and distribute the drug in USA, Japan and Europe while Ranbaxy retains rights in the other markets. The 500 mg Cipro-D molecule licensed to Bayer AG has completed its clinical trials and the Bayer has filed an NDA (New Drug Application). It may be noted that following approval from the authorities, it would reach the commercialisation stage. This could trigger a considerable milestone payment for Ranbaxy. Considering the time taken by regulatory authorities for approval, we expect launch of Cipro-D by mid-2003, ahead of original Ciprofloxacin patent expiry in 2003 end.
Ranbaxy has ramped up its product approvals in last few months for the international markets. The latest one being, generic manufacturing and marketing approval for all combinations of Lisinopril drug, which is a multi-billion cardiovascular molecule. The company currently has a basket of 47 products for the US markets, far ahead of any other Indian generic company. As mentioned earlier, the US geography recorded 185% growth for 1HFY03. Even excluding Ceftin sales, formulations sales in the US registered an impressive 95% growth for the first half of the current year. European sales growth was also encouraging at 36%. There has been a sharp improvement in the global performance of the company for the second quarter as is evident from the above table. The company's targeted penetration in Germany, Brazil and UK seems to be working well.
Consolidated Results Snapshot
|Operating Margins (%)
At the current market price of Rs 916, the stock is trading at 19x 1HFY03 annualised earnings on a consolidated basis. The results are well above our expectations. The company seems all set to cross US$ 100 m net profit for FY03. Considering rapid ANDA (Abbreviated New Drug Applications) and expanding export portfolio of the company, the company clearly has well laid out infrastructure to lead the lucrative generic opportunity.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
May 30, 2017
US markets decline while other geographies grow in the quarter.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
TRACK RANBAXY LAB
- Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks